(NASDAQ: KNSA) Kiniksa Pharmaceuticals's forecast annual revenue growth rate of 29.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Kiniksa Pharmaceuticals's revenue in 2024 is $270,259,000.On average, 2 Wall Street analysts forecast KNSA's revenue for 2024 to be $26,113,788,211, with the lowest KNSA revenue forecast at $25,866,282,559, and the highest KNSA revenue forecast at $26,361,293,863. On average, 2 Wall Street analysts forecast KNSA's revenue for 2025 to be $33,339,823,412, with the lowest KNSA revenue forecast at $31,456,873,850, and the highest KNSA revenue forecast at $35,222,772,974.
In 2026, KNSA is forecast to generate $41,750,637,452 in revenue, with the lowest revenue forecast at $36,746,645,148 and the highest revenue forecast at $46,754,629,756.